Cargando…

In vitro and in vivo quantification of chloroprocaine release from an implantable device in a piglet postoperative pain model

BACKGROUND: The pharmacokinetic properties and clinical advantages of the local anesthetic chloroprocaine are well known. Here, we studied the pharmacokinetic profile of a new hydrogel device loaded with chloroprocaine to investigate the potential advantages of this new strategy for postoperative pa...

Descripción completa

Detalles Bibliográficos
Autores principales: De Gregori, Simona, De Gregori, Manuela, Bloise, Nora, Bugada, Dario, Molinaro, Mariadelfina, Filisetti, Claudia, Allegri, Massimo, Schatman, Michael E, Cobianchi, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231440/
https://www.ncbi.nlm.nih.gov/pubmed/30510443
http://dx.doi.org/10.2147/JPR.S180163
Descripción
Sumario:BACKGROUND: The pharmacokinetic properties and clinical advantages of the local anesthetic chloroprocaine are well known. Here, we studied the pharmacokinetic profile of a new hydrogel device loaded with chloroprocaine to investigate the potential advantages of this new strategy for postoperative pain (POP) relief. MATERIALS AND METHODS: We performed both in vitro and in vivo analyses by considering plasma samples of four piglets receiving slow-release chloroprocaine. To quantify chloroprocaine and its inactive metabolite 4-amino-2-chlorobenzoic acid (ACBA), a HPLC–tandem mass spectrometry (HPLC-MS/MS) analytical method was used. Serial blood samples were collected over 108 hours, according to the exposure time to the device. RESULTS: Chloroprocaine was consistently found to be below the lower limit of quantification, even though a well-defined peak was observed in every chromatogram at an unexpected retention time. Concerning ACBA, we found detectable plasma concentrations between T(0) and T(12h), with a maximum plasma concentration (C(max)) observed 3 hours after the device application. In the in vitro analyses, the nanogel remained in contact with plasma at 37°C for 90 minutes, 3 hours, 1 day, and 7 days. Chloroprocaine C(max) was identified 1 day following exposure and C(min) after 7 days, respectively. Additionally, ACBA reached the C(max) following 7 days of exposure. CONCLUSION: A thorough review of the literature indicates that this is the first study analyzing both in vivo and in vitro pharmacokinetic profiles of a chloroprocaine hydrogel device and is considered as a pilot study on the feasibility of including this approach to the management of POP.